title: Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection.
abstract: Human metapneumovirus (hMPV) is an important cause of lower respiratory tract disease, particularly in infants and young children. hMPV has two major glycoproteins, G and F, which are responsible for virus attachment and membrane fusion, respectively. We investigated the role of cellular glycosaminoglycans (GAGs) and G protein in hMPV infection. The pretreatment of hMPV with soluble heparin markedly inhibited the infection of HEp-2 cells. Recombinant G protein, comprising the extracellular domain of G, bound to heparin-agarose columns and also to HEp-2 cells. hMPV infection and G protein binding to HEp-2 cells was inhibited by other soluble GAGs, including chondroitin sulfates, by the enzymatic removal of cell surface GAGs with GAG lyases or by the pretreatment of cells with basic fibroblast growth factor. The role of cellular GAGs was confirmed by the binding of G protein to wild-type CHO cells but not to GAG-deficient CHO-pgsA745 cells. An analysis of the G protein sequence revealed two adjacent clusters of positively charged amino acids ((149)EKKKTRA(155) and (159)QRRGKGKE(166)). Truncated G fragments were expressed, and only the fragment containing these putative heparin binding domains retained heparin binding. The alanine mutagenesis of charged residues in either of these regions resulted in the loss of binding to heparin and to HEp-2 cells, suggesting that both sites are likely to be required for hMPV attachment. These results, taken together with the inhibition of hMPV infection by soluble G protein, indicate an important role for G protein and cellular GAGs in hMPV infection.
authors.affiliation: Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Bedford Park, SA 5042, Australia.
authors.forename: Sutthiwan
authors.initials: S
authors.lastname: Thammawat
authors.forename: Tania A
authors.initials: TA
authors.lastname: Sadlon
authors.forename: Peter G
authors.initials: PG
authors.lastname: Hallsworth
authors.forename: David L
authors.initials: DL
authors.lastname: Gordon
mesh_terms: D000818:Animals; D016264:Dextran Sulfate / Q000494:pharmacology; D006025:Glycosaminoglycans / Q000502:physiology*; D006493:Heparin / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007067:Iduronic Acid / Q000494:pharmacology; D008253:Macaca mulatta; D029121:Metapneumovirus; D018184:Paramyxoviridae Infections / Q000209:etiology*; D011485:Protein Binding; D014759:Viral Envelope Proteins / Q000502:physiology*
chemical_list: D006025:Glycosaminoglycans; D014759:Viral Envelope Proteins; C116204:attachment protein G; D007067:Iduronic Acid; D006493:Heparin; D016264:Dextran Sulfate
references.citation: Arteriosclerosis. 1989 Jan-Feb;9(1):21-32
references.pmid: 2463827
references.citation: Biochimie. 2001 Aug;83(8):811-7
references.pmid: 11530214
references.citation: Eur J Immunol. 2003 Apr;33(4):962-9
references.pmid: 12672062
references.citation: Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3546-50
references.pmid: 7724595
references.citation: Virology. 2002 Mar 30;295(1):119-32
references.pmid: 12033771
references.citation: Virology. 2002 Mar 15;294(2):296-304
references.pmid: 12009871
references.citation: Antimicrob Agents Chemother. 1991 Dec;35(12):2515-20
references.pmid: 1725692
references.citation: Clin Microbiol Rev. 2006 Jul;19(3):546-57
references.pmid: 16847085
references.citation: J Virol. 2005 Oct;79(19):12608-13
references.pmid: 16160190
references.citation: J Virol. 2002 Jun;76(12):6164-71
references.pmid: 12021350
references.citation: Antiviral Res. 2004 Jul;63(1):51-9
references.pmid: 15196820
references.citation: J Biol Chem. 1993 Sep 15;268(26):19228-31
references.pmid: 8366075
references.citation: J Virol. 2000 Jul;74(14):6442-7
references.pmid: 10864656
references.citation: J Virol. 2000 Nov;74(22):10508-13
references.pmid: 11044095
references.citation: J Virol. 2003 Mar;77(5):3269-80
references.pmid: 12584350
references.citation: J Virol. 2004 Dec;78(23):12877-87
references.pmid: 15542640
references.citation: Arch Virol. 2003 Oct;148(10):1987-2003
references.pmid: 14551820
references.citation: Arch Virol. 1997;142(6):1247-54
references.pmid: 9229012
references.citation: J Virol. 1998 Sep;72(9):7349-56
references.pmid: 9696831
references.citation: J Infect Dis. 2002 Jun 1;185(11):1660-3
references.pmid: 12023774
references.citation: Virology. 2003 Oct 10;315(1):1-9
references.pmid: 14592754
references.citation: J Gen Virol. 1996 Jun;77 ( Pt 6):1249-57
references.pmid: 8683213
references.citation: J Virol. 2001 Jul;75(14):6303-9
references.pmid: 11413296
references.citation: Biochemistry. 1990 Mar 13;29(10):2611-7
references.pmid: 2334685
references.citation: Virology. 2002 Jan 5;292(1):162-8
references.pmid: 11878919
references.citation: Virology. 2000 Jun 5;271(2):264-75
references.pmid: 10860881
references.citation: Methods Mol Biol. 2007;379:15-34
references.pmid: 17502668
references.citation: J Biol Chem. 1992 May 25;267(15):10337-41
references.pmid: 1587820
references.citation: J Gen Virol. 2004 Mar;85(Pt 3):679-686
references.pmid: 14993653
references.citation: J Virol. 2007 Dec;81(24):13435-43
references.pmid: 17913798
references.citation: Nat Med. 2001 Jun;7(6):719-24
references.pmid: 11385510
references.citation: Virology. 2001 Oct 25;289(2):283-96
references.pmid: 11689051
references.citation: Proc Natl Acad Sci U S A. 1985 May;82(10):3197-201
references.pmid: 3858816
references.citation: J Virol. 1998 Sep;72(9):7357-66
references.pmid: 9696832
references.citation: J Virol. 1999 Aug;73(8):6610-7
references.pmid: 10400758
references.citation: J Clin Microbiol. 2004 Aug;42(8):3532-7
references.pmid: 15297494
references.citation: Antimicrob Agents Chemother. 1988 Nov;32(11):1742-5
references.pmid: 2472775